Dr. Stanley Jordan

Medical Director
Cedars-sinai Medical Center
USA

Dr. Stanley Jordan has dedicated his career to improving transplant outcomes for patients with high levels of HLA and ABO incompatibility. He pioneered the first desensitization protocol in 1990, leading to major clinical trials and the approval of IVIG and Rituximab for treating highly sensitized patients. He founded the Transplant Immunotherapy Program at Cedars-Sinai in 2004, which continues to drive innovation in antibody rejection therapies. His groundbreaking research includes the use of C1 inhibitors, IgG endopeptidase (imlifidase), and anti-IL-6 therapies, many of which are now in advanced clinical trials. With over 400 publications and multiple patents, Dr. Jordan’s work has earned numerous prestigious awards, including the Medawar Prize, the highest honor in transplantation science.